NCT05003752View on ClinicalTrials.gov

Hypo-Combi Trial: Hypofractionated EBRT Plus HDR-BT Boost for Prostate Cancer

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 1, 2021

Primary Completion Date

December 31, 2022

Study Completion Date

August 1, 2026

Conditions
Prostate AdenocarcinomaRadiation Toxicity
Interventions
RADIATION

External beam radiation therapy, High-dose-rate brachytherapy

Combined hypofractionated external beam radiation therapy (EBRT) plus high dose-rate brachytherapy (HDR-BT) schedule (total dose of EBRT 36 Gy/ in 12 fractions of 3 Gy plus HDR-BT with a total physical dose of 14 Gy in a single fraction)

DRUG

Goserelin 10.8 mg

Androgen deprivation will be administered based on NCCN guidelines in patients with unfavorable intermediate/high risk organ-confined prostate cancer

Trial Locations (1)

4108

German Oncology Center, Limassol

All Listed Sponsors
lead

German Oncology Center, Cyprus

OTHER